Jakarta, CNBC Indonesia – The British pharmaceutical company AstraZeneca says its Covid-19 antibody has helped reduce the risk of serious symptoms and even death. This was described in her last stage study.
Reported by Al JazeeraThis drug with two antibodies called AZD7442 reduces the risk of severe Covid-19 symptoms when dying by up to 50% in patients who are not in the hospital.
However, AstraZeneca, which is given by injection, became the first preventive medicine and as a treatment for Covid-19 after several trials. It is designed to protect people who do not have a strong enough immune response to the vaccine.
“These positive results suggest that a convenient intramuscular dose of AZD7442 may play an important role in combating this devastating pandemic,” Hugh Montgomery, lead researcher on the trial, said Monday.
A similar therapy made with a class of drugs called monoclonal antibodies is being developed by Regeneron, Eli Lilly and GlaxoSmithKline with partner Vir Biotechnology.
This therapy is approved for emergency use in the United States (US) for the treatment of mild to moderate symptoms of COVID-19.
Last week, AstraZeneca asked the US Food and Drug Administration (FDA) to provide clearance for emergency use of AZD7442 as a preventative therapy. According to the spokesperson, AstraZeneca has also submitted data from several studies of the AZD7442 to global health regulators.
“We will continue discussions with supervisors about this new data,” he said of Monday’s test results.
The trial took place in 13 countries and involved more than 900 adult participants, half of whom received AZD7442 and the rest in placebo. The full test results will be submitted for publication in a peer-reviewed journal, according to AstraZeneca.
AZD7442 contains laboratory antibodies designed to stay in the body for months to contain the virus in the event of an infection. Instead, vaccines rely on an intact immune system to develop targeted antibodies and fight cells against infections.
While the results of the use of AZD7442 in non-hospital patients, a separate trial is also studying its use as a treatment for hospital Covid-19 patients.